At 10.3% CAGR, Asia Pacific Embolization Devices Market is Projected to be Worth US$ 1,302.34 Million by 2031, Says Business Market Insights

According to Business Market Insights' research, the Asia Pacific embolization devices market was valued at US$ 659.10 in 2024 and is expected to reach US$ 1,302.34 million by 2031, registering a CAGR of 10.3% from 2025 to 2031. New product developments and marketing approvals and burgeoning demand for minimally invasive techniques are among the critical factors attributed to the Asia Pacific embolization devices market expansion.

Small and big companies operating in the embolization devices market are increasingly adopting strategies such as geographic expansions, new product developments, and technological advancements to boost their revenues. A few of the noteworthy product developments and approvals in the embolization devices market, which are expected to drive its growth in the coming years, are mentioned below.

• In January 2024, the National Medical Products Administration provided marketing approval for the ZYLOX Phoenix Peripheral Detachable Fibered Coil Embolization System manufactured by Zylox-Tonbridge Medical Technology Co Ltd. ZYLOX Phoenix is an innovative, proprietary medical device designed for the minimally invasive interventional treatment of peripheral arterial embolism. Peripheral vascular intervention is the most prevalent application of this embolization coil system. Embolization treatment of visceral aneurysms, and the endoleak management of abdominal aortic aneurysms, hemoptysis, and arteriovenous fistula are the other important clinical applications of the system. With regulatory approval for the use in these applications, the system has received international recognition for its safety and efficacy.
• In October 2023, Sirtex Medical announced the commercial launch of the Lava Liquid Embolic System (LES), approved for the treatment of peripheral vascular hemorrhage. According to the company, Lava offers customizable volume and viscosity options to enable precise and controlled occlusion of target vessels. Available in 2-mL and 6-mL configurations, the system is specifically optimized for use in the peripheral vasculature. Its range of viscosities allows for effective distal embolization, reaching small and otherwise inaccessible vessels where other embolic agents may be less effective.

Therefore, new product developments and marketing approvals are anticipated to create lucrative growth opportunities in the embolization devices market.

On the contrary, complications arising during or after embolization hampers the growth of Asia Pacific embolization devices market.

Based on type, the Asia Pacific embolization devices market is segmented into embolization coils, plugs, beads, glues, and others. The embolization coils segment held 60.9% share of the Asia Pacific embolization devices market in 2024, amassing US$ 401.65 million. It is projected to garner US$ 812.45 million by 2031 to expand at 10.7% CAGR during 2025-2031. The embolization coils segment is further sub segmented into central application and peripheral application.

Based on application, the Asia Pacific embolization devices market is segmented into neurology, peripheral vascular disease, oncology, urology, and others. The neurology segment held 41.0% share of the Asia Pacific embolization devices market in 2024, amassing US$ 269.98 million. It is projected to garner US$ 553.77 million by 2031 to expand at 10.9% CAGR during 2025-2031.

Based on end user, the Asia Pacific embolization devices market is segmented into hospitals, ambulatory centers, and others. The hospitals segment held 56.2% share of the Asia Pacific embolization devices market in 2024, amassing US$ 370.33 million. It is projected to garner US$ 754.11 million by 2031 to expand at 10.8% CAGR during 2025-2031.

Based on country, the Asia Pacific embolization devices market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China held 28.0% share of Asia Pacific embolization devices market in 2024, amassing US$ 184.78 million. It is projected to garner US$ 377.44 million by 2031 to expand at 10.9% CAGR during 2025-2031.

Key players operating in the embolization devices market are Medtronic Plc; Cook Medical Holdings LLC; Stryker Corp; Boston Scientific Corp; Terumo Corp; Johnson & Johnson; Abbott Laboratories; NeuroSafe Medical Co. Ltd; Wallaby Medical; Sirtex Medical Ltd; GEM srl; Penumbra Inc.; Balt; Lepu Medical Technology Beijing Co Ltd; INVAMED; Meril Life Sciences Pvt Ltd; Merit Medical Systems Inc; and Lifetech Scientific Corp, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com